Poprach A - Search Results

1

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).

Santini D, Li H, Roviello G, Park SH, Grande E, Kucharz J, Basso U, Fiala O, Monteiro FSM, Poprach A, Buti S, Molina-Cerrillo J, Catalano M, Buchler T, Seront E, Ansari J, Myint ZW, Ghosn M, Calabrò F, Kopp RM, Bhuva D, Bourlon MT, Roberto M, Di Civita MA, Mollica V, Marchetti A, Soares A, Battelli N, Ricci M, Kanesvaran R, Bamias A, Porta C, Massari F, Santoni M. Santini D, et al. Among authors: poprach a. Target Oncol. 2024 Nov;19(6):893-903. doi: 10.1007/s11523-024-01096-3. Epub 2024 Sep 17. Target Oncol. 2024. PMID: 39289313

2

Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database.

Poprach A, Bortlíček Z, Büchler T, Melichar B, Lakomý R, Vyzula R, Brabec P, Svoboda M, Dušek L, Gregor J. Poprach A, et al. Med Oncol. 2012 Dec;29(5):3314-20. doi: 10.1007/s12032-012-0286-9. Epub 2012 Jun 30. Med Oncol. 2012. PMID: 22752571

3

Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.

Buchler T, Pavlik T, Bortlicek Z, Poprach A, Vyzula R, Abrahamova J, Melichar B. Buchler T, et al. Among authors: poprach a. Med Oncol. 2012 Dec;29(5):3321-4. doi: 10.1007/s12032-012-0293-x. Epub 2012 Jun 30. Med Oncol. 2012. PMID: 22752573

4

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.

Poprach A, Pavlik T, Melichar B, Kubackova K, Bortlicek Z, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Buchler T; Czech Renal Cancer Cooperative Group. Poprach A, et al. Urol Oncol. 2014 May;32(4):488-95. doi: 10.1016/j.urolonc.2013.09.011. Epub 2013 Dec 8. Urol Oncol. 2014. PMID: 24321257

5

Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.

Kiss I, Bortlicek Z, Melichar B, Poprach A, Halamkova J, Vyzula R, Dusek L, Buchler T. Kiss I, et al. Among authors: poprach a. Anticancer Res. 2014 Feb;34(2):949-54. Anticancer Res. 2014. PMID: 24511038

6

Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.

Buchler T, Bortlicek Z, Poprach A, Kubackova K, Kiss I, Zemanova M, Fiala O, Dusek L, Vyzula R, Melichar B; Czech Renal Cancer Cooperative Group. Buchler T, et al. Among authors: poprach a. Urol Oncol. 2014 Jul;32(5):569-75. doi: 10.1016/j.urolonc.2013.12.007. Epub 2014 Mar 12. Urol Oncol. 2014. PMID: 24629497

7

Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency.

Poprach A, Bortlicek Z, Melichar B, Lakomy R, Svoboda M, Kiss I, Zemanova M, Fiala O, Kubackova K, Coufal O, Pavlik T, Dusek L, Vyzula R, Buchler T. Poprach A, et al. Eur J Cancer. 2015 Mar;51(4):507-513. doi: 10.1016/j.ejca.2014.12.010. Epub 2015 Jan 7. Eur J Cancer. 2015. PMID: 25577735

8

Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.

Kubackova K, Melichar B, Bortlicek Z, Pavlik T, Poprach A, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Prausova J, Buchler T; Czech Renal Cancer Cooperative Group. Kubackova K, et al. Among authors: poprach a. Target Oncol. 2015 Dec;10(4):557-63. doi: 10.1007/s11523-015-0366-9. Target Oncol. 2015. PMID: 25903462

9

High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib.

Fiala O, Pesek M, Finek J, Topolcan O, Racek J, Minarik M, Benesova L, Bortlicek Z, Poprach A, Buchler T. Fiala O, et al. Among authors: poprach a. Tumour Biol. 2015 Dec;36(12):9215-22. doi: 10.1007/s13277-015-3660-3. Epub 2015 Jun 19. Tumour Biol. 2015. PMID: 26088452

10

Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.

Buchler T, Bortlicek Z, Poprach A, Pavlik T, Veskrnova V, Honzirkova M, Zemanova M, Fiala O, Kubackova K, Slaby O, Svoboda M, Vyzula R, Dusek L, Melichar B; Czech Renal Cancer Cooperative Group. Buchler T, et al. Among authors: poprach a. Eur Urol. 2016 Sep;70(3):469-75. doi: 10.1016/j.eururo.2015.12.031. Epub 2015 Dec 30. Eur Urol. 2016. PMID: 26746623

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters